Colon | Pancreas | Rectum, Phase II
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Selected Solid Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. The treatment will be given to patients every three weeks.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Barbara Burtness, MD
- David Witt, MD
- Hari Deshpande, MD
- James Vredenburgh, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Larisa Fleysher
- Lynsey Teulings
- Madeline Santiago
- Melissa Gambaccini
- Michael Cecchini, MD
- Michael Chiorazzi, MD, PhD
- Michael Cohenuram, MD
- Michelle Laspino
- Neal Fischbach, MD
- Ninani Kombo, MD
- Pawan Karanam, MD
- Stacey Stein, MD
- Last Updated04/12/2024
- Study HIC#2000022891